VCP Scanner
Stock Screener
Filter stocks with fundamental & technical criteria
Market Themes
Curated industry baskets & thematic leaders
Earnings Hub
Calendar, EPS surprise stats & earnings transcripts
Market News
Real-time market intelligence & AI overviews
Insider Buying
SEC Form 4 corporate insider purchases
MinerviniVCP SetupsTrend Template
O'NeilCup with HandleFlat BaseDouble BottomCANSLIM Leaders
QullamaggieHigh Tight FlagsFlag BreakoutsEpisodic PivotsMomentum Leaders
KellWedge PopEMA Crossback
LivermorePivotal Points
PatternsFalling Wedge & ChannelBase Breakouts
View All Playbooks...
BreakoutsScanner
FAANG & Tech
AAPL vs MSFTNVDA vs AMDGOOGL vs META
Cloud & Cyber
CRM vs NOWCRWD vs PANWSNOW vs DDOG
Consumer & Auto
TSLA vs FAMZN vs WMTNFLX vs DIS
Finance & Crypto
JPM vs BACV vs MACOIN vs MSTR
Index & ETFs
SPY vs QQQVTI vs VOOSPY vs IWM
Compare Any Stocks...
DCF ValuationCalculate intrinsic value of US stocks
Market ValuationBuffett indicator, CAPE & macro gauges
Total ReturnSee dividends + price return history
DCA CalculatorSimulate recurring buys & compounding
VisualizeInteractive multi-year financial charts
Watchlist
BreakoutsScanner
WatchlistPricing
Ctrl K
Pricing
VKTX
← Back to Screener
VCP ScannerFree US Stock Screener & Financial Analysis

Find stocks. Analyze deeply. Research with clarity.

Data updated daily

Product

  • Screener
  • Scanner
  • Themes
  • Valuation
  • Total Return
  • DCA Calculator
  • Pricing
  • News
  • Earnings

Resources

  • Market Valuation
  • Compare
  • Insider Activity
  • Methodology
  • How It Works
  • Glossary
  • Learn

Get Ideas

Get weekly market insights — free

© 2026 VCP Scanner
AboutPrivacyTermsRefund Policy
Not financial advice. Do your own research.
ScreenerBreakoutsScannerWatchlist
VKTXViking Therapeutics, Inc.
$26.84$3.1B
Overview & Tools
OverviewChart Terminal ↗Visualize
Valuation & Forecasts
Valuation ModelsEstimatesDCF Model
Price & Analyst Data
Analyst TargetsPrice History
Financial Statements
Income StatementBalance SheetCash FlowRatios & Margins
Performance
P/E HistoryRevenue HistoryEarnings HistoryDividend HistoryTotal Return
Discovery & Screens
Live BreakoutsStock ScreenerOwnership
HomeStocksVKTXCash Flow

Viking Therapeutics, Inc. (VKTX) Cash Flow Statement

14Y historyFree accessUpdated daily

Operating cash outflow of -$138.2M in 2026Q3 tracks closely with net losses (OCF/NI near 0.75 to 1.0 in recent quarters), indicating losses are largely cash-driven, with no capex or shareholder returns and cash burn concentrated in development spending.

Income StatementBalance SheetCash FlowRatios

VKTX Cash Flow Statement

Annual statement

VKTX Cash Flow Statement

Viking Therapeutics, Inc. (VKTX) cash flow statement — 14-year operating, investing & financing cash flows

AnnualQuarterly
MetricTTMDec'25Dec'24Dec'23Dec'22Dec'21Dec'20Dec'19Dec'18Dec'17Dec'16Dec'15Dec'14Dec'13Dec'12
Cash from Operations-462.63M-278.69M-87.79M-73.38M-48.4M-47.59M-21.78M-24.75M-18.75M-14.76M-11.07M-8.73M-1.59M-78.23K-200
Operating CF Margin %---------------
Operating CF Growth %-504.32%-217.45%-19.64%-51.61%-1.7%-118.51%12.02%-31.98%-27.09%-33.3%-26.8%-448.66%-1934.16%-39017.5%-
Net Income-627.2M-359.64M-109.96M-85.89M-68.87M-54.99M-39.49M-25.78M-22.06M-20.58M-14.73M-23.4M-21.88M-146.25K-444
Depreciation & Amortization336K431K346K292K291K296K277K260K26.16M19.07M1.93M1.03M000
Stock-Based Compensation47.95M40.82M29.71M16.75M8.67M6.1M5.82M3.74M2.61M1.45M1.79M2.6M6.26K422
Deferred Taxes00000000-392K-1.28M-1.79M-893.5K000
Other Non-Cash Items-4.43M-9.27M-17.25M-8.07M1.32M3.94M3.91M807K-25.89M-15.19M877.65K11.32M-1.65M42.57K244
Working Capital Changes120.71M48.98M9.36M3.55M10.19M-2.93M7.72M-3.78M823K1.77M849.88K620.32K21.94M25.44K0
Change in Receivables1.47M5.08M1.2M321K614K1.18M000000000
Change in Inventory000000000000000
Change in Payables77.72M43.44M2.3M-1.02M7.08M-2.54M1.55M1.47M-508K263.51K677.18K219.24K190.3K20.06K0
Cash from Investing331.75M341.39M-553.37M-179.09M54.75M37.96M41.57M7.46M-265.73M-1.73M3.03M-13.47M000
Capital Expenditures000000000000000
CapEx % of Revenue---------------
Acquisitions000000000000000
Investments---------------
Other Investing125.69M00054.75K000-265.73K-1.73K3.03K-13.47K000
Cash from Financing708.32M76.44M612.46M271.38M4.16M6.88M950K887K300.27M22.4M10.35M22.21M2.17M257.85K200
Debt Issued (Net)251M0000000-3.83M-77K-94.86K02.5M260.35K0
Equity Issued (Net)349.17M2.49M597.09M269.76M-8.33M7.59M1.25M1.04M296.61M22.35M11.55M25.39M-2-2.5K0
Dividends Paid000000000000000
Share Repurchases0000-6.79M00000-229-38-2-2.5K0
Other Financing108.15M73.95M15.37M1.62M12.49M-707K-296K-151K7.5M125.45K-1.1M-3.18M-332.34K0200
Net Change in Cash577.22M139.13M-28.84M18.88M10.26M-2.75M20.74M-16.4M15.79M5.91M2.31M12.69K576.24K179.62K0
Free Cash Flow-462.63M-278.69M-87.79M-73.38M-48.4M-47.59M-21.78M-24.75M-18.75M-14.76M-11.07M-8.73M-1.59M-78.23K-200
FCF Margin %---------------
FCF Growth %-106%-217.45%-19.64%-51.61%-1.7%-118.51%12.02%-31.98%-27.09%-33.3%-26.8%-448.66%-1934.16%-39017.5%-
FCF per Share-3.92-2.47-0.81-0.78-0.63-0.62-0.30-0.34-0.33-0.57-0.68-1.37-0.37-0.02-0.13
FCF Conversion (FCF/Net Income)0.74x0.77x0.80x0.85x0.70x0.87x0.55x0.96x0.85x0.72x0.75x0.37x0.07x0.53x0.45x
Interest Paid000000000000000
Taxes Paid000000000000000

Key Metrics

Growth RegimeMixed
ProfitabilityNegative
Balance SheetMixed
Cash FlowBurning
Top Statement Risk

Accelerating cash burn

Verified Source

Metrics are mathematically derived from official filings.

SEC 10-K (2026Q3)

Losses Mirror Operating Cash Burn

Based on reported figures, VKTX's operating cash flow has tracked closely with its net losses over the last ten quarters, with OCF/NI ratios ranging from 0.54 to 1.28, suggesting the reported losses are largely cash-driven rather than dominated by non-cash charges. The conversion profile indicates the deficit is real and not an accounting artifact. Investors should monitor whether this relationship persists as operating spending scales further.

The 2026Q3 operating cash outflow of $138.2M against a net loss of $183.2M yields an OCF/NI ratio of 0.75, meaning roughly three-quarters of the reported loss consumed cash in the period. Stock-based compensation of $17.9M explains a meaningful portion of the gap, but the remaining difference is consistent with the cash-intensive nature of clinical-stage R&D spending. Because the company reports no revenue, the cash cost of research is effectively the entire burn story rather than a timing issue in collections.

Free Cash Flow Deficit Widening Steadily

Based on EDBL's reported figures, VKTX's free cash flow deficit expanded from roughly -$22.0M in 2024Q3 to -$138.2M in 2026Q3, with no offsetting revenue to support the outflow. The trajectory signals a sustained acceleration in cash consumption as pipeline spending scales. Free cash flow margin is not meaningful given the absence of reported revenue.

Free cash flow has been negative in every quarter presented, and the quarterly burn has risen more than sixfold over roughly two years, with a notable step-up through 2025 and 2026. Because capital expenditures are reported as zero, the entire free cash flow figure reflects operating outflows tied to research and administrative activity. Without revenue, traditional FCF margin analysis offers little insight, so the more relevant measure is the length of runway implied by the current burn rate, which the supplied data does not fully disclose.

Asset-Light Model Keeps Capex Minimal

As reported in financial statements, VKTX recorded no capital expenditures across the ten quarters provided, indicating an asset-light operating model centered on outsourced or intangible-driven development. This keeps the cash burn concentrated in operating expenses rather than fixed investment. The absence of capex means depreciation is also negligible, consistent with limited physical infrastructure.

Zero capex and near-zero depreciation and amortization suggest the company is not building manufacturing or lab infrastructure on its balance sheet during this period. This structure lowers capital intensity but also means cash spending is fully exposed to clinical trial and personnel costs, leaving little flexibility to defer investment. Investors may wish to confirm whether development activities are contracted out, since that affects how quickly spending can be scaled up or cut.

Capital Consumed Entirely by Operations

According to recent SEC filings, VKTX paid no dividends, repurchased no shares, and reported no acquisitions over the periods provided, so all cash resources were directed toward funding operating losses. This leaves capital deployment as a single-purpose question of sustaining development spending. The absence of shareholder returns is expected for a loss-making biotech.

With no buybacks, dividends, or acquisitions, the entire cash position is being drawn down to fund operations, making the balance sheet cash level and any external financing the critical variables. The supplied data does not disclose cash balances or financing activity, so the adequacy of current resources cannot be assessed from this dataset. Analysts should cross-reference the balance sheet and recent financing disclosures to judge how many quarters of runway remain at the current burn.

Working Capital Swings Obscure Underlying Burn

Based on reported figures, VKTX's working capital changes have been volatile, swinging from a $65.5M inflow in 2025Q4 to a $15.1M outflow in 2025Q1, which may temporarily mask or exaggerate the underlying operating burn. Quarterly operating cash flow is therefore a noisy read of run-rate spending. Investors should look at multi-quarter averages rather than single periods.

The large 2025Q4 working capital inflow of $65.5M coincided with an operating cash outflow of only $85.3M, meaning the underlying cash burn before that timing benefit was materially larger. Such swings typically reflect accrued liability timing rather than improving economics, and they may reverse in subsequent periods. Treating the most recent quarter as a clean baseline risks understating the true cash consumption rate.

VKTX — Frequently Asked Questions

Quick answers to the most common questions about buying VKTX stock.

How much cash does Viking Therapeutics, Inc. (VKTX) generate from operations?

Viking Therapeutics, Inc. (VKTX) generated $-278.7M in net cash from operating activities in 2025. This reflects the cash generated directly from core business operations.

What is Viking Therapeutics, Inc.'s free cash flow?

Viking Therapeutics, Inc. (VKTX) reported negative free cash flow of $278.7M in 2025, indicating capital requirements exceeded cash from operations.

What is Viking Therapeutics, Inc.'s capital expenditure (CapEx)?

Viking Therapeutics, Inc. (VKTX) spent $0.0M on capital expenditures in 2025. CapEx represents the cash invested in physical assets like property, plant, and equipment to maintain or grow the business.